Gapping up
M&A news:
- AJRD +1.6% (to be acquired by L3Harris Technologies (LHX) for $58.00/share in an all-cash transaction valued at $4.7 billion, inclusive of net debt), .
Other news:
- MDGL +150.8% (announces positive topline results from pivotal Phase 3 MAESTRO-NASH Clinical Trial of resmetirom)
- ZYME +26.9% (announces "positive" topline results from the pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab, as monotherapy in patients with previously treated HER2-amplified and expressing BTC)
- TSHA +16.8% (announces executive leadership changes; Chair of the Board of Directors, Sean Nolan, appointed CEO)
- MESA +6.8% (plans for a significant restructuring in its operations with American Airlines (AAL) and United Airlines)
- ZIP +5.6% (enters $50 mln share repurchase program)
- BLUE +3.1% (FDA lifts partial clinical hold for BLUE Sickle Cell Disease Studies for Patients Under the Age of 18),
Analyst comments:
- MRNA +3.5% (upgraded to Buy from Hold at Jefferies),